Trial intelligence / Profile preview

Phase IIb placebo-controlled study of intravenous cinaciguat in acute decompensated chronic congestive heart failure

2009-014377-40Phase 2Terminated

Sponsor
Bayer
Start
Nov 2009
Modality
Small Molecules
Countries
1
01

Overview

Phase 2, randomised, double-blind trial of cinaciguat in heart failure (HF) (4 arms), sponsored by Bayer. Primary endpoint: Change in pulmonary capillary wedge pressure from baseline to 8 hours. Started Nov 2009; status: terminated.

02

Drugs

cinaciguat
03

Conditions

heart failure (HF)

Beyond the preview

Go deeper on 2009-014377-40.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2009-014377-40.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call